Document:

Document

Exhibit 10.7

						
	Lockheed Martin Corporation 
6801 Rockledge Drive Bethesda, MD 20817 
Telephone 301-897-6000	

January 27, 2022
Jesus Malave, Jr.
[Address Redacted]

Dear Jay, 

I am pleased to offer you the position of Chief Financial Officer (CFO), reporting to James D. Taiclet, Chairman, President and Chief Executive Officer.  The position will be located in Bethesda, MD.  Your start date will be January 31, 2022 or such other date mutually agreed by you and the Corporation. 

Your initial base salary will be $960,000 per year.  Base salaries are reviewed annually.  You will be paid on a weekly basis, with one week in arrears.  You will be paid a one-time cash sign-on bonus of $750,000, which is subject to applicable taxes and other withholdings, within 30 days of your start date but no earlier than the first payroll cycle in 2022 to offset annual incentive amounts you will forfeit when you terminate your current employment.  If you voluntarily terminate or otherwise leave employment for reasons within your own control or are terminated for cause within one (1) year from the date of commencement of service, you will reimburse Lockheed Martin the hiring bonus(es) paid to you.

Your annual incentive target opportunity under the Corporation’s Management Incentive Compensation Plan (MICP) will be 115% of your base salary for 2022.  Because you will start after January 1, 2022, your award will be pro-rated based on your start date.  Payouts are generally made in early March following the performance year and range from 0-200% of your target opportunity based on performance results relative to pre-established goals that are established in February of the plan year. Payouts for elected officers are subject to review and approval by the Board of Directors. 

You will be nominated to receive a one-time special long-term incentive (LTI) award of $4,000,000 in restricted stock units (RSUs) that if granted will vest 100% one year from the date of grant to offset unvested incentive awards you will forfeit when you terminate your current employment. You will also be nominated for an LTI award of $8,000,000 in February 2022, $4,000,000 of which is also to offset unvested incentive awards you will forfeit when you terminate your current employment. This $8,000,000 LTI award will be allocated 50% in Performance Stock Units (PSUs), 30% in Restricted Stock Units (RSUs) and 20% in the cash-based Long-Term Incentive Performance award (LTIP).  The RSUs if granted will cliff vest 100% three years from the date of grant while the PSUs and LTIP if granted will vest in February 2025 based on the Corporation’s performance over the three-year performance period (2022-2024) relative to the three-year performance goals established by the Corporation’s Management Development and Compensation Committee (the Committee) for the 2022-2024 performance period. These awards are expected to be granted in February 2022 and are subject to review and approval by the Committee and the terms of the applicable award agreements approved by the Committee, which include restrictive covenants related to non-competition, non-solicitation, non-disparagement, and confidentiality. Awards will be based on the fair value on the date of grant as determined by the Committee.  

Since this position will require you to relocate, you will also be entitled to relocation benefits under our applicable relocation policy, a copy of which will be provided to you.  You will also be entitled to participate in the Corporation’s qualified savings plan with a 401(k) feature, as well as non-qualified supplemental savings plans, and our suite of health and welfare benefits available to salaried employees.  Lockheed Martin reserves the right to amend or to terminate its benefits plans at any time.  

All amounts payable hereunder shall be subject to any required withholding and deductions.  

While we are confident that we will have a satisfactory employment relationship, Lockheed Martin is an at-will employer and you will serve at the discretion of the Board of Directors.  This means that either you or Lockheed Martin may end the employment relationship for any or no reason and without advance notice.  If this offer is acceptable, please sign below.  

I am very pleased to make this offer and look forward to you joining the executive leadership team.

Sincerely, 

/s/ James D. Taiclet
James D. Taiclet
Chairman, President and Chief Executive Officer

Offer Acceptance :
			
	
	/s/ Jesus Malave, Jr.
	Jesus Malave, Jr.Document

Exhibit 10.8

LOCKHEED MARTIN CORPORATION
DEFERRED MANAGEMENT INCENTIVE COMPENSATION PLAN
(As Amended and Restated Generally Effective January 1, 2020)

Amendment No. 2

Lockheed Martin Corporation wishes to revise the Lockheed Martin Corporation Deferred Management Incentive Compensation Plan (Plan) to reflect the current annual incentive plan payments that may be deferred under the Plan, to clarify when prospective payment election changes become irrevocable, and to incorporate gender-neutral pronouns into the Plan.  Accordingly, the Plan is revised as follows.
1.    Section 24 of Article II of the Plan is amended in its entirety to read as follows:
“24.    MICP – The Lockheed Martin Corporation 2021 Management Incentive Compensation Plan and the Lockheed Martin Corporation Attorney Incentive Plan, Amended and Restated Effective January 1, 2021.”
2.    Section 4(d) of Article V of the Plan is amended in its entirety to read as follows:
“4(d)    Notwithstanding anything to the contrary in this Article V, a Participant may make a new election with respect to the commencement of payment and form of payment with respect to any sub-account maintained for Award Years or a Death Benefit or with respect to his or her entire Account Balance.  A new election under this section shall be made by executing and delivering to the Company an election in such form as prescribed by the Company, and shall be irrevocable upon the earlier of the Participant’s Termination of Employment with the Company or twelve (12) months from the date that the change in election is delivered to the Company.  To constitute a valid election by a Participant making a prospective change to a previous election, (i) the prospective election must be executed and delivered to the Company at least twelve (12) months before the date the first payment would be due under the Participant’s previous election, and (ii) the first payment must be delayed by at least sixty (60) months from the date the first payment would be due under the Participant’s previous election, and (iii) such change in election shall not be given effect until twelve (12) months from the date that the change in election is delivered to the Company.  In the event an election fails to satisfy the provisions set forth in this paragraph, such election shall be void and, if such an election is void, payment shall be made in accordance with the most recent election which was valid.”
3.    Article IX of the Plan is amended by added a new section 11 to read as follows:
“11. Gender-Neutral Pronouns.    Notwithstanding anything in the Plan to the contrary, unless the context clearly indicates otherwise, wherever the masculine or feminine is used in this Plan, the same is intended, and shall be understood and interpreted to include all individuals, of any gender, or those who do not identify with any gender.  Similarly, the words she, her, hers, herself, he, him, his, himself, they, them, their, theirs, or themself as used in this Plan apply universally regardless of gender.”

                                                            LOCKHEED MARTIN CORPORATION

                                               						
	By:	/s/ Greg Karol  

		Greg Karol
		Senior Vice President, Chief Human Resources Officer 
	Date: 	12/16/2021Document

               Exhibit 10.9

LOCKHEED MARTIN CORPORATION CONSOLIDATED SUPPLEMENTAL RETIREMENT BENEFIT PLAN

Clarifying Changes

Lockheed Martin Corporation wishes to amend the Lockheed Martin Corporation Consolidated Supplemental Retirement Benefit Plan (the “Plan”) so as to make certain clarifying changes. Accordingly, the Plan is amended as follows.
1.    Effective January 1, 2021, any reference in the Plan to a Pension Benefit Guaranty Corporation or PBGC lump sum interest rate shall be the lump sum interest rate determined using the methodology set forth in 29 CFR Appendix C to Part 4022 (Lump Sum Interest Rates for Private-Sector Payments).
2.    The first sentence of Section 4 of Article III of the Plan is amended and restated in its entirety, reading as follows:
Notwithstanding any other provision of the Plan, the accrued benefit of each Participant shall be one hundred percent (100%) vested and be distributed in a single lump sum within fifteen (15) calendar days following a “Change in Control.”

    LOCKHEED MARTIN CORPORATION

                                                         						
	By:	/s/ Greg Karol  

		Greg Karol
		Senior Vice President, Chief Human Resources Officer 
	Date: 	12/15/2021EX-10.1

 Exhibit 10.1 

EXECUTION COPY 
 AMENDMENT
NO. 2 
 Dated as of April 15, 2022 

to 
 CREDIT AGREEMENT 

Dated as of April 15, 2019 

THIS AMENDMENT NO. 2 (this “Amendment”) is made as of April 15, 2022 by and among
Bio-Rad Laboratories, Inc. (the “Borrower”), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative
Agent’), under that certain Credit Agreement, dated as of April 15, 2019, by and among the Borrower, the Lenders and the Administrative Agent (as further amended, restated, supplemented or otherwise modified from time to time, the
“Credit Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Credit Agreement. 

WHEREAS, the Borrower has requested that the requisite Lenders and the Administrative Agent agree to make certain amendments to the Credit
Agreement; and 
 WHEREAS, the Borrower, the Lenders party hereto and the Administrative Agent have so agreed on the terms and conditions
set forth herein; 
 NOW, THEREFORE, in consideration of the premises set forth above, the terms and conditions contained herein, and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrower, the Lenders party hereto and the Administrative Agent hereby agree to enter into this Amendment. 

1. Amendments to the Credit Agreement. Effective as of the date of satisfaction of the conditions precedent set forth in
Section 2 below, the parties hereto agree to amend the Credit Agreement as follows: 
 (a) Section 1.1 of the
Credit Agreement is hereby amended to replace the definition of “Leverage Ratio” in its entirety to read as follows: 

““Leverage Ratio” means, as of any date of calculation, the ratio of (i) the sum of (a) Consolidated Funded
Indebtedness outstanding on such date, minus (b) the aggregate amount of all unencumbered cash and Cash Equivalent Investments of the Borrower held on deposit that, in the aggregate, exceeds $200,000,000, to (ii) Consolidated EBITDA for
the Borrower’s then most-recently ended four fiscal quarters.” 
 (b) Section 6.1 of the Credit Agreement is hereby amended to
(i) delete the reference to “ninety (90) days” in clause (i) thereof and replace such reference with “one hundred-twenty (120) days” and (ii) delete the reference to “forty-five (45) days”
in clause (ii) thereof and replace such reference with “sixty (60) days”. 
 2. Conditions of Effectiveness. The
effectiveness of this Amendment is subject to the satisfaction of the following conditions precedent:  

(a) The Administrative Agent shall have received counterparts of this Amendment duly executed by the Borrower, the Lenders and the
Administrative Agent. 

 (b) The Administrative Agent shall have received payment of the Administrative Agent’s
and its affiliates’ reasonable and documented out-of-pocket expenses (including reasonable and documented out-of-pocket fees and expenses of one counsel for the Administrative Agent) in connection with this Amendment. 

3. Representations and Warranties of the Borrower. The Borrower hereby represents and warrants as follows: 

(a) This Amendment and the Credit Agreement, as modified, hereby constitute legal, valid and binding obligations of the Borrower, enforceable
in accordance with their terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a
proceeding in equity or at law. 
 (b) As of the date hereof and after giving effect to the terms of this Amendment, (i) no Unmatured
Default or Default has occurred and is continuing and (ii) the representations and warranties contained in Article V of the Credit Agreement (as amended hereby) are true and correct in all material respects (or, in the case of any
representation or warranty qualified by materiality or Material Adverse Effect, in all respects), except to the extent any such representation or warranty is stated to relate solely to an earlier date, in which case such representation or warranty
was true and correct in all material respects (or, in the case of any representation or warranty qualified by materiality or Material Adverse Effect, in all respects) on and as of such earlier date. 

4. Reference to and Effect on the Credit Agreement. 

(a) Upon the effectiveness hereof, each reference to the Credit Agreement in the Credit Agreement or any other Loan Document shall mean and be
a reference to the Credit Agreement as amended hereby. 
 (b) The Credit Agreement and all other documents, instruments and agreements
executed and/or delivered in connection therewith shall remain in full force and effect and are hereby ratified and confirmed. 
 (c) The
execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Administrative Agent or the Lenders, nor constitute a waiver of any provision of the Credit Agreement or any other documents,
instruments and agreements executed and/or delivered in connection therewith. 
 (d) This Amendment is a Loan Document. 

5. Governing Law. This Amendment shall be construed in accordance with and governed by the law of the State of New York. 

6. Headings. Section headings in this Amendment are included herein for convenience of reference only and shall not constitute a part
of this Amendment for any other purpose. 

  
 2 

 7. Counterparts. This Amendment may be executed by one or more of the parties hereto
on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Signatures delivered by facsimile or PDF shall have the same force and effect as manual signatures
delivered in person. Delivery of an executed counterpart of a signature page of this Amendment by fax, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page shall be effective as delivery of a
manually executed counterpart of this Amendment. For the avoidance of doubt, the provisions of Article XIV of the Credit Agreement apply to this Amendment. 

[Signature Pages Follow] 

  
 3 

 IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first above
written. 
  

					
	 BIO-RAD LABORATORIES, INC.,

as the Borrower

		
	By:	 	/s/ Andy Kim
	Name:	 	Andy Kim
	Title:	 	VP, Treasurer

  

  
 Signature Page to
Amendment No. 2 to 
 Credit Agreement dated as of April 15, 2019 

Bio-Rad Laboratories, Inc. 

 
					
	 JPMORGAN CHASE BANK, N.A.,

individually as a Lender, and as Administrative Agent

		
	By:	 	/s/ Gregory T. Martin
	Name:	 	Gregory T. Martin
	Title:	 	Executive Director

  

  
 Signature Page to
Amendment No. 2 to 
 Credit Agreement dated as of April 15, 2019 

Bio-Rad Laboratories, Inc. 

 
			
	BANK OF AMERICA, N.A., as a Lender
		
	By:	 	/s/ Sebastian Lurie
	Name:	 	Sebastian Lurie
	Title:	 	SVP

 Signature Page to Amendment No. 2 to 

Credit Agreement dated as of April 15, 2019 

Bio-Rad Laboratories, Inc. 

 
			
	HSBC BANK USA NATIONAL ASSOCIATION, as a Lender
		
	By:	 	/s/ Marie Alava
	Name:	 	Marie Alava
	Title:	 	SVP- Relationship Manager

 Signature Page to Amendment No. 2 to 

Credit Agreement dated as of April 15, 2019 

Bio-Rad Laboratories, Inc. 

 
			
	MUFG UNION BANK, N.A., as a Lender
		
	By:	 	/s/ Jack Lonker
	Name:	 	Jack Lonker
	Title:	 	Authorized Signer

 Signature Page to Amendment No. 2 to 

Credit Agreement dated as of April 15, 2019 

Bio-Rad Laboratories, Inc. 

 
			
	CITIBANK, N.A., as a Lender
		
	By:	 	/s/ Eugene Yermash
	Name:	 	Eugene Yermash
	Title:	 	Vice President

 Signature Page to Amendment No. 2 to 

Credit Agreement dated as of April 15, 2019 

Bio-Rad Laboratories, Inc. 

 
			
	WELLS FARGO BANK, NATIONAL
ASSOCIATION, as a Lender
		
	By:	 	/s/ Eugene Stunson
	Name:	 	Eugene Stunson
	Title:	 	Director

 Signature Page to Amendment No. 2 to 

Credit Agreement dated as of April 15, 2019 

Bio-Rad Laboratories, Inc. 

 
			
	BANK OF THE WEST, as a Lender
		
	By:	 	/s/ Adriana Collins
	Name:	 	Adriana Collins
	Title:	 	Director

 Signature Page to Amendment No. 2 to 

Credit Agreement dated as of April 15, 2019 

Bio-Rad Laboratories, Inc. 

 
			
	CITIZENS BANK, N.A., as a Lender
		
	By:	 	/s/ Benjamin Silero
	Name:	 	Benjamin Silero
	Title:	 	VP

 Signature Page to Amendment No. 2 to 

Credit Agreement dated as of April 15, 2019 

Bio-Rad Laboratories, Inc. 

 
			
	U.S. BANK NATIONAL ASSOCIATION, as a Lender
		
	By:	 	/s/ David C. Mruk
	Name:	 	David C. Mruk
	Title:	 	SVP

 Signature Page to Amendment No. 2 to 

Credit Agreement dated as of April 15, 2019 

Bio-Rad Laboratories, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]